Clinical Trials
214 trialsStudy of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
TEJAS-2
Aurigene Discovery Technologies Limited
CLEAR
Harbinger Health
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
ALAFOSS-01
AstraZeneca
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune, Inc.
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Informed Choice - Compass
Exact Sciences Corporation
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Amgen
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
CLAUDE
Enterome
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Incyte Corporation
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
RELATIVITY-123
Bristol-Myers Squibb
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Incyte Corporation
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
SAFE-2
SafeHeal Inc
ELEVATE CRC
Gilead Sciences
A Study to Investigate LYL845 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Daiichi Sankyo
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
MasterKey-01
Black Diamond Therapeutics, Inc.
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Mirati Therapeutics Inc.